SAN CARLOS, Calif. - Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) reported fourth quarter 2024 financial results that fell short of analyst expectations on the revenue front, sending shares down 5.3% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback